AstraZeneca announces initiation of THARROS – a Phase III clinical trial investigating the potential of BREZTRI to improve cardiopulmonary outcomes in people with COPD

THARROS is the first-ever prospective trial to investigate the potential of an inhaled triple therapy to reduce cardiopulmonary events, a key driver of mortality, in COPD


First patients dosed in...

Related Keywords

United States ,Japan ,New York ,China ,Netherlands ,Smeeth ,Kent ,United Kingdom ,Cambridge ,Cambridgeshire ,Americans ,Fernando Martinez ,Sharon Barr ,Formoterol Fumarate ,European Respiratory Society Congress ,National Heart ,Division Of Pulmonary ,Global Initiative On Obstructive Lung Disease ,Blood Institute ,Centers For Disease ,Astrazeneca ,Global Initiative For Chronic Obstructive Lung Disease ,International Investigator ,Data Network ,Harvard Medical School ,Critical Care Medicine ,Weill Cornell Medicine ,New York Presbyterian Hospital ,International Co Ordinating Investigator ,Associate Physician ,Executive Vice President ,Important Safety ,Astrazeneca Biopharmaceuticals ,Rare Diseases ,Study Evaluating ,Formoterol Fumarate Metered Dosed Inhaler ,Cardiopulmonary Outcomes ,Chronic Obstructive Pulmonary Disease ,Metered Dose Inhaler ,Exercise Parameters ,Eur Respir ,Post Hoc Cohort Analysis ,Respir Crit Care Med ,Future Risk ,United Kingdom Routine Health Care Data ,Intj Chron Obstruct Pulmon ,General Practice Based Population ,Chronic Obstructive Pulmonary ,Obstructive Lung Disease ,Atherosclerosis Risk ,Global Initiative ,Chronic Obstructive Lung Disease ,Disease Control ,Leading Causes ,